Steven Cohen’s Cytokinetics CYTK Stock Holding History

Steven Cohen’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51.1K	Sell	600 -6,300	-91%	-$452K	﹤0.01%	3789
2026 Q1	$455K	Sell	6,900 -4,200	-38%	-$267K	﹤0.01%	3158
2025 Q4	$705K	Sell	11,100 -18,900	-63%	-$1.18M	﹤0.01%	3055
2025 Q3	$1.65M	Sell	30,000 -25,000	-45%	-$1.03M	﹤0.01%	1521
2025 Q2	$1.82M	Buy	+55,000	New	+$1.91M	﹤0.01%	1347
2024 Q4	–	Sell	-40,000	Closed	-$2.11M	–	2137
2024 Q3	$2.11M	Buy	40,000 +20,000	+100%	+$1.11M	0.01%	1179
2024 Q2	$1.08M	Buy	+20,000	New	+$1.21M	﹤0.01%	1254
2024 Q1	–	Sell	-220,000	Closed	-$18.4M	–	2270
2023 Q4	$18.4M	Buy	220,000 +180,000	+450%	+$6.52M	0.04%	457
2023 Q3	$1.18M	Buy	+40,000	New	+$1.33M	﹤0.01%	1280

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's CYTK Position: Q2 2026 in Review

Steven Cohen increased its Cytokinetics (CYTK) stake by 154% in Q2 2026, buying an estimated $69M and bringing the position to 1,587,712 shares worth $135M. The position accounts for 0.15% of the portfolio, ranked #140.

Steven Cohen first reported a position in CYTK in Q2 2019 and has held it in 25 quarters since. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Steven Cohen held 1,587,712 shares of Cytokinetics worth $135M as of Q2 2026.
Steven Cohen bought 961,610 Cytokinetics shares in Q2 2026, an estimated $69M.
Cytokinetics made up 0.15% of Steven Cohen's portfolio in Q2 2026, its #140 holding.
Steven Cohen first reported a position in Cytokinetics in Q2 2019 and has held it in 25 quarters since.
479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.